Skip to main content
OpenTrials
Completed

NCT Number: NCT04882631

A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants

This is an open-label, single-arm, randomized, evaluator-blinded repeat insult patch testing (RIPT) study wherein test product is applied under an occlusive dressing to the upper back or arm continuously and repeatedly to the same site for a period of 21 days.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

KGL Skin Study Center

Newtown Square, Pennsylvania, 19073, United States

About this study

This is an open-label, single-arm, randomized, evaluator-blinded repeat insult patch testing (RIPT) study wherein test product is applied under an occlusive dressing to the upper back or arm continuously and repeatedly to the same site for a period of 21 days. Three concentrations of PBI-100 Topical Cream and vehicle (placebo cream) will be applied to the skin of each subject. In addition, one site will be treated with a positive control and another site will be treated with a plain cotton cloth patch and will serve as a negative control.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult male and female volunteers between the ages of 18 and 70 years with Fitzpatrick types I, II, or III.
  • Must be willing to follow the study requirements and voluntarily give their informed consent.
  • Subjects must be able to read and follow study instructions in English.
  • Generally in good health as determined by the investigator, based on medical history interview.
  • Evidence of a personally signed and dated Informed Consent indicating that the subject has been informed of and understood all pertinent aspects of the trial.

Exclusion criteria

  • Scars, moles, or other blemishes over the forearm, upper arm, or back that interfere with the study.
  • Sunburn within the last three weeks or use of tanning beds.
  • History of allergy or hypersensitivity to skin care or consumer products including fragrances, cosmetics, toiletries, or any kind of tape.
  • History of chronic or recurrent dermatological diseases, e.g., psoriasis, atopic eczema, chronic urticaria.
  • Subjects receiving systemic or topical drugs which can interfere with the development of an inflammatory response, e.g., steroids, immunosuppressive agents, or retinoids.
  • History of any significant systemic diseases e.g., cardiac, pulmonary, renal, hepatic, etc. that would impact subject's ability to complete the study.
  • Pregnancy or mothers who are breastfeeding or planning a pregnancy.
  • Other conditions considered by the Investigator as sound reasons for disqualification from enrollment into the study.

Treatment and study plan

PBI-100 Topical Cream

Drug

A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.

Positive Control - Sodium laurel sulfate (SLS)

Drug

Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.

Other names: SLS

PBI-100 Topical Cream, Vehicle

Other

Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.

Negative Control

Other

A blank patch was applied daily (excluding weekends) as a negative control test site.

Primary outcomes

  1. Irritation Potential

    Time frame: 21 days

    Irritation potential based on the Cumulative Irritation Index (CII)

Sponsors and collaborators

Lead sponsor

Pyramid Biosciences

Industry

Registry information

Official study title

A 21 Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants Using a Cumulative Irritant Patch Test Design

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
May 12, 2021
Registry last updated
Jan 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.